Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27040163 | 1.00 | IRAK4 (0.41) | IRAK4P2RX3TNFTRPA1AAK1 | |
| SCHEMBL27040161 | 1.00 | IRAK4 (0.41) | IRAK4P2RX3TNFTRPA1AAK1 | |
| SCHEMBL16873172 | 0.86 | IRAK4 (0.43) | IRAK4P2RX3TNFTRPA1ATR | |
| SCHEMBL27039419 | 0.82 | SCN9A (0.39) | IRAK4P2RX3TRPA1AAK1ATR | |
| SCHEMBL27039418 | 0.82 | SCN9A (0.39) | IRAK4P2RX3TRPA1AAK1ATR | |
| SCHEMBL31291010 | 0.82 | SCN9A (0.39) | IRAK4P2RX3TRPA1AAK1ATR | |
| SCHEMBL12931891 | 0.78 | ATR (0.47) | P2RX3TRPA1AAK1ATRCA12 | |
| SCHEMBL31323887 | 0.75 | IRAK4 (0.61) | IRAK4 | |
| SCHEMBL22837208 | 0.75 | IRAK4 (0.61) | IRAK4 | |
| SCHEMBL27040003 | 0.74 | IRAK4 (0.60) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735424-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250042906-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2025006946-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042906-A1 | PROCESSES FOR MAKING IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK2 | IRAK4 1/4885P2RX3 3720/4885TNF 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.